ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Proposed Guidelines For Clinical Tests Of Oncologic Drugs

November 28, 1975

DCPC Board approves New CCOP RFA Following Addition Of Public Health, Education Components

May 16, 1986

Nine More state To Pay For Cancer Treatment Of CDC-Screened Women.

September 7, 2001

Breast Cancer Risk Rises To 1 Woman In 9

February 1, 1991

DCBD Board Rejects Breast Cancer Multiple Markers Concept Proposal

November 4, 1983

NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation

June 12, 1992